Question 1

Is tesofensine a peptide?

Accepted Answer

No. Tesofensine is a small-molecule triple reuptake inhibitor, not a peptide. It is included in peptide catalogs because it is frequently discussed alongside peptide-based weight-loss therapies and sourced from similar research-chemical suppliers.

Question 2

How does tesofensine compare to semaglutide for weight loss?

Accepted Answer

Phase II data showed 12.8% weight loss over 24 weeks with tesofensine 0.5 mg. Semaglutide 2.4 mg achieves ~15% over 68 weeks in STEP trials. Tesofensine may work faster but has less long-term safety data and cardiovascular concerns at higher doses. Semaglutide is FDA-approved; tesofensine is not.

Question 3

Why was tesofensine development stopped?

Accepted Answer

Development stalled primarily due to the original company's (NeuroSearch) financial difficulties, not safety signals per se. Higher doses showed elevated heart rate and blood pressure. The drug was acquired by Saniona, which is pursuing it in combination with metoprolol (Tesomet) specifically for hypothalamic obesity — a rare condition where GLP-1s are often ineffective.

Question 4

What are the main side effects of tesofensine?

Accepted Answer

The most common side effects in trials were dry mouth, insomnia, constipation, and elevated heart rate. At the 1.0 mg dose, heart rate increases of 7–8 bpm and systolic blood pressure rises were observed. The 0.5 mg dose had a more favorable cardiovascular profile.

Question 5

Can tesofensine be combined with GLP-1 agonists?

Accepted Answer

There are no published combination studies. The mechanisms are complementary (central monoamine vs incretin pathways), but the combination would carry additive cardiovascular and gastrointestinal risk. This would require careful medical oversight and is not a standard approach.

Question 6

What is Tesomet?

Accepted Answer

Tesomet is Saniona's combination product pairing tesofensine with metoprolol (a beta-blocker) to counteract the heart-rate elevation. It is in clinical development specifically for hypothalamic obesity — a condition caused by damage to the hypothalamus where standard weight-loss therapies usually fail.

Question 7

Why does tesofensine have such a long half-life and what does that mean for dosing?

Accepted Answer

Tesofensine has a half-life of approximately 200 hours (~8 days), which is unusually long for an oral weight-loss agent. This means it takes several weeks to reach steady-state blood levels and, importantly, side effects may persist for days after discontinuation. The long half-life supports once-daily dosing but also means dose adjustments require patience, as the full effect of any change may not be apparent for 2–3 weeks.

Question 8

Is tesofensine legal to buy and is it FDA-approved?

Accepted Answer

Tesofensine is not FDA-approved, EMA-approved, or approved by any major regulatory agency for any indication. It has no scheduled drug classification in most countries, which creates a legal gray area where it is sold as a research chemical. Purchasing it for personal use carries risks including unknown purity, lack of medical oversight, and no legal consumer protections.

Question 9

How is tesofensine different from phentermine or other stimulant-based diet drugs?

Accepted Answer

While phentermine primarily stimulates norepinephrine release, tesofensine is a reuptake inhibitor that blocks the recycling of serotonin, norepinephrine, and dopamine simultaneously. This triple-action mechanism targets appetite, thermogenesis, and food reward pathways concurrently, which likely explains its stronger weight-loss efficacy in trials. However, the dopamine reuptake inhibition also raises theoretical concerns about abuse potential that have not been fully evaluated in long-term studies.

Question 10

Does tesofensine affect mood or cognitive function?

Accepted Answer

Tesofensine was originally developed for neurodegenerative diseases, and its monoamine reuptake inhibition profile overlaps with that of some antidepressants (serotonin/norepinephrine) and ADHD medications (dopamine/norepinephrine). Phase II obesity trials reported improved subjective well-being in some participants, but the compound has not been rigorously studied for psychiatric outcomes. Because it modulates all three major monoamine systems, individuals taking antidepressants, ADHD medications, or MAO inhibitors should be particularly cautious about dangerous interactions.

Origin / Manufacturer	Synthetic (small molecule)
Active Components	Tesofensine hydrochloride
Storage	Room temperature, protected from light
Shelf Life	24+ months (capsule form)
Form Factor	Oral capsule (0.25 mg, 0.5 mg, 1.0 mg)

Tesofensine

Specifications

Clinical Evidence

Frequently Asked Questions

Related Peptides

5-Amino-1MQ

AOD-9604

Semaglutide

Tirzepatide